Envoy Medical Faces Delisting Concerns
Ticker: COCHW · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1840877
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Envoy Medical might get delisted, big trouble for shareholders.
AI Summary
Envoy Medical, Inc. filed an 8-K on October 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly Anzu Special Acquisition Corp I, is based in White Bear Lake, MN, and operates in the orthopedic, prosthetic & surgical appliances & supplies industry. The filing indicates potential issues with its continued listing on the stock exchange.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact investor confidence and the company's ability to trade publicly.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's public trading status and indicates significant underlying issues.
Key Numbers
- 001-40133 — SEC File Number (Identifier for the company's filings)
- 86-1369123 — EIN (Employer Identification Number)
Key Players & Entities
- Envoy Medical, Inc. (company) — Registrant
- Anzu Special Acquisition Corp I (company) — Former company name
- October 23, 2025 (date) — Earliest event date
- October 28, 2025 (date) — Report date
- 3842 (number) — Standard Industrial Classification
FAQ
What specific rule or standard has Envoy Medical, Inc. failed to satisfy, leading to the potential delisting?
The filing does not specify the exact rule or standard that Envoy Medical, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 23, 2025.
What was Envoy Medical, Inc.'s former name?
Envoy Medical, Inc.'s former name was Anzu Special Acquisition Corp I.
What is Envoy Medical, Inc.'s Standard Industrial Classification code?
Envoy Medical, Inc.'s Standard Industrial Classification code is 3842, which pertains to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
On what date was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on October 28, 2025.
Filing Stats: 667 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-10-28 09:22:49
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
- $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
- $35 million — tion to demonstrate compliance with the $35 million market value of listed securities requi
Filing Documents
- ea0262700-8k_envoy.htm (8-K) — 33KB
- ea026270001ex99-1_envoy.htm (EX-99.1) — 14KB
- 0001213900-25-102828.txt ( ) — 260KB
- coch-20251023.xsd (EX-101.SCH) — 4KB
- coch-20251023_def.xml (EX-101.DEF) — 26KB
- coch-20251023_lab.xml (EX-101.LAB) — 36KB
- coch-20251023_pre.xml (EX-101.PRE) — 25KB
- ea0262700-8k_envoy_htm.xml (XML) — 6KB
01 Notice of Delisting or Failure to Satisfy a Continued
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On October 23, 2025, the Nasdaq Hearings Panel (the "Panel") notified Envoy Medical, Inc. (the "Company) that it has granted the Company's request for an exception to demonstrate compliance with the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement") for continued listing through February 23, 2026 (the "Exception"). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company's ability to satisfy the terms of the Exception. As previously disclosed, the Company initially received a notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on February 25, 2025 indicating that the Company was not in compliance with the MVLS Requirement. Also as previously disclosed, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period, which determination letter informed the Company that it can request a hearing regarding Nasdaq's determination with the Panel. The Hearing was held on October 2, 2025.
01 Other Events
Item 8.01 Other Events On October 27, 2025, the Company issued a press release regarding the Panels grant of the Exception. A copy of the press release is attached hereto and incorporated by reference herein as Exhibit 99.1. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Envoy Medical, Inc. Press Release, dated October 27, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. October 28, 2025 By: /s/ Brent T. Lucas Brent T. Lucas Chief Executive Officer 2